Dalbavancin Study Results to be Presented at IDWeek 2013

Dalbavancin Study Results to be Presented at IDWeek 2013

CHICAGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced that data from the company's lead product
candidate, dalbavancin, will be presented in five posters during the IDWeek
conference in San Francisco from October 2-6, 2013.

The following posters will be presented on Saturday, October 5, 2013:

Title: An Analysis of the Safety Profile of Dalbavancin from the Phase 2/3
Clinical Program

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Anita Das, PhD,
InClin, San Francisco, CA and Sailaja Puttagunta, MD, Durata Therapeutics,
Branford, CT

Poster #: 1334

Title: Microbiologic Analyses of Target Pathogens Identified in the
Dalbavancin DISCOVER Program

Authors: Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Helen
Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, Mark Wilcox, MD,
Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United
Kingdom, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and George
Talbot, MD, Talbot Advisors LLC, Anna Maria, FL

Poster #: 1338

Title: An Integrated Analysis of the Efficacy of Dalbavancin in the Treatment
of Acute Bacterial Skin and Skin Structure Infections (abSSSI) from the
DISCOVER Program

Authors: Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and
University of Leeds, Leeds, United Kingdom, Helen Boucher, MD, FIDSA, Tufts
New Engl Med Ctr, Boston, MA, George Talbot, MD, Talbot Advisors LLC, Anna
Maria, FL, Anita Das, PhD, InClin, San Francisco, CA, Sailaja Puttagunta, MD,
Durata Therapeutics, Branford, CT and Michael Dunne, MD, Durata Therapeutics,
Inc., Branford, CT

Poster #: 1339

Title: Concordance of Clinical Response at 48-72 hours after Initiation of
Therapy and End of Treatment (EOT) in Patients with Acute Bacterial Skin and
Skin Structure Infection (abSSSI) in the DISCOVER Studies

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Sailaja
Puttagunta, MD, Durata Therapeutics, Branford, CT, Mark Wilcox, MD,
Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United
Kingdom, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL and Helen
Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA

Poster #: 1340

Title: Clearance of Staphylococcus aureus Bacteremia in Patients Treated with
Dalbavancin

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT and Sailaja
Puttagunta, MD, Durata Therapeutics, Branford, CT

Poster #: 1343

Durata will display the five posters from Thursday, October 3 at 10:00 a.m.
until Saturday, October 5 at 6:00 p.m.

In addition, Laura Koeth and Jeanna Difranco-Fisher (Laboratory Specialists,
Inc.) will present In vitro Activity of Dalbavancin against Neisseria
gonorrhoeae and Development of a Broth Microdilution Method (Poster #: 255) on
Thursday, October 3, 2013. This research was supported by a grant from Durata
Therapeutics.

The abstracts are currently available on the IDWeek website at www.idweek.org
and copies of the posters will be available on October 2, 2013 at 12:01 am PDT
at www.duratatherapeutics.com.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation
for once-weekly dosing, which we believe may facilitate the treatment of
patients with ABSSSI in both the in-patient and out-patient settings,
potentially reducing the length of a patient's hospital stay or avoiding
hospital admission altogether, with an impact on the overall cost of care for
these patients.

About Durata Therapeutics, Inc.

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.

About IDWeek 2013

IDWeek is the combined annual meeting of the Infectious Diseases Society of
America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the
HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases
Society (PIDS). With the theme—Advancing Science, Improving Care—IDWeek
features the latest science and bench-to-bedside approaches in prevention,
diagnosis, treatment, and epidemiology of infectious diseases, including HIV,
across the lifespan. IDWeek will be held in the Moscone Convention Center, 747
Howard Street, San Francisco, CA 94103, October 2-6, 2013.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.

Forward-looking statements in this press release include statements about the
impact of once-weekly dosing of dalbavancin. Actual results may differ
materially from those indicated by these forward-looking statements as a
result of various important factors, including those discussed in the "Risk
Factors" section of our most recent quarterly report on Form 10-Q, which is on
file with the SEC and is also available on our website. In addition, any
forward-looking statements represent our views only as of today and should not
be relied upon as representing our views as of any subsequent date. While we
may elect to update these forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so, even if our views
change. Therefore, you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey
         Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         awey@duratatherapeutics.com
        
         Media Relations Contact
         Geoff Curtis
         DJE Science
         (312) 233-1253

Durata Therapeutics, Inc. Logo